1.. Introduction {#s1}
================

The transcription factor *CITED2* binds the histone acetyltransferase CREBBP/EP300 with high affinity,^[@CVN101C1]^ acting as a co-activator for transcription factors, such as TFAP2, LHX2, PPARA, and SMAD2/3.^[@CVN101C2]^ It also acts as a repressor of hypoxia-activated transcription.^[@CVN101C1]^ Genetic evidence indicates that *Cited2* is essential for cardiac, adrenal, neural, and placental development, and also for embryonic left--right patterning.^[@CVN101C6]^ The cardiac malformations in mice lacking *Cited2* are highly penetrant and phenotypically heterogeneic, and include atrial, atrioventricular, and ventricular septal defects (ASD, AVSD, VSD), outflow tract defects \[double outlet right ventricle (DORV), common arterial trunk (CAT), tetralogy of Fallot (TOF), transposition of great arteries (TGA)\], and interrupted and right-sided aortic arch.^[@CVN101C6],[@CVN101C9]^ Mutation in *Cited2* also results in adrenal agenesis, fusion of cranial ganglia, abnormal cardiac neural crest migration, and exencephaly.^[@CVN101C6]^

In addition, *Cited2^−/−^* mice show left--right patterning defects characterized by right atrial and pulmonary isomerism, and abnormal ventricular topology at a lower penetrance.^[@CVN101C7],[@CVN101C8]^ Cardiovascular left--right patterning is created, in part, by the left-determining *Nodal→Pitx2c* pathway (reviewed by Hamada *et al*.^[@CVN101C10]^ and Ramsdell^[@CVN101C11]^). Genetic evidence shows that *Cited2* is necessary for expression of *Pitx2c*, *Nodal*, and *Lefty2* in the left-lateral plate mesoderm and of *Lefty1* in the prospective floor plate, and is present at the promoter of the endogenous *Pitx2c* gene during development.^[@CVN101C7],[@CVN101C8]^ Thus, *Cited2* is necessary for *Nodal*-activated gene transcription.^[@CVN101C7]^ The mechanism for the cardiovascular phenotypic heterogeneity and the partial penetrance of left--right patterning defect, which is observed even on a congenic *Cited2*-deficient background,^[@CVN101C7]^ is not clear. Importantly, loss-of-function mutations in *CITED2* have been found in patients with phenotypically variable congenital heart disease.^[@CVN101C12]^ These mutations are heterozygous, suggesting haploinsufficiency, but the mechanism for this is unclear.

*Cited2* is expressed before gastrulation in the visceral endoderm.^[@CVN101C13]^ Following gastrulation it is present in the newly forming mesoderm, developing blood islands, cardiac crescent, presomitic and splanchnic mesoderm, cranial neuroectoderm, and migrating neural crest before becoming ubiquitously expressed by embryonic day (E)8.5.^[@CVN101C13]^ In the heart, it is highly expressed in the AV endocardial cushions.^[@CVN101C8]^ One possible mechanism for cardiac phenotypic heterogeneity in *Cited2* deficiency is that not only is it required for the earlier process of left--right patterning but also independently for the later processes of atrioventricular septation, outflow tract, and aortic arch development.^[@CVN101C8]^ Abnormal patterning of aortic arches and CAT observed in *Cited2* deficiency could, for instance, arise from defective neural crest development.^[@CVN101C6]^ An alternative possibility is that an abnormality in the earlier developmental process of left--right patterning may secondarily affect the subsequent processes of atrioventricular septal, outflow tract, or aortic arch development.^[@CVN101C7]^ These different mechanisms were investigated with a conditional knockout approach. We also investigated the mechanism of haploinsufficiency using quantitative analysis of *Cited2* and its target gene *Pitx2c*. We show that the phenotypic heterogeneity in *Cited2* deficiency is because of a primary requirement in epiblast derivatives with a secondary cell-autonomous role in the mesoderm. Also, *Cited2* haploinsufficiency may cause cardiac malformation by reducing expression of key *Cited2* targets such as *Pitx2c*.

2.. Methods {#s2}
===========

2.1. Molecular biology {#s2a}
----------------------

Standard molecular biology procedures were used for plasmid constructions.^[@CVN101C14]^

2.2. Generation of Cited2^flox/flox^ mice {#s2b}
-----------------------------------------

The targeting vector strategy and generation of correctly targeted embryonic stem cells with a conditional *Cited2* allele (*Cited2^flox^* or *Cited2^f^*) is shown in [Supplementary material online, *Figure S1*](#sup1){ref-type="supplementary-material"}. Methods are also provided in detail in the [Supplementary data](#sup1){ref-type="supplementary-material"}. The allele was designed such that, after successful *Cre* recombination, a *lacZ* expression cassette came under the control of the endogenous *Cited2* promoter. This allowed indication of efficient recombination by β-galactosidase staining.

2.3. Conditional deletion of *Cited2* {#s2c}
-------------------------------------

*Cited2^+/−^* mice (*Cited2^tm1Bha^*) on a C57BL/6J background^[@CVN101C7]^ were crossed with *Sox2Cre* (Tg(Sox2-cre)1Amc),^[@CVN101C15]^*Wnt1Cre* (Tg(Wnt1-cre)11Rth)^[@CVN101C16]^ (both gifts from Andrew McMahon, Harvard University), *Mesp1Cre* (Mesp1tm2(cre)Ysa)^[@CVN101C17]^ or *TCre*^[@CVN101C18]^ mice to generate males with *Cited2^+/−^*;*Cre* genotypes. These males were crossed to *Cited2^flox/flox^* females on a mixed 129Sv × C57BL/6J background to generate embryos with *Cited2^−/flox^;Cre* and *Cited2^+/flox^;Cre* (control) genotypes. This strategy prevented global recombination owing to *Cre* expression in the maternal germline.^[@CVN101C19]^*Cited2^−/flox^;Cre* embryos lack *Cited2* expression in cells expressing *Cre*-recombinase. *Cited2^+/flox^;Cre* embryos continue to express *Cited2*, providing littermate controls. Embryos were harvested at the indicated time points after the detection of a vaginal plug (E0.5), and genotyped using allele-specific polymerase chain reaction (PCR) (primer details are available on request). All mouse experiments conform with the *Guide for the Care and Use of Laboratory Animals* published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996).

2.4. Analysis of embryos {#s2d}
------------------------

Magnetic resonance imaging (MRI) was performed on a horizontal 9.4 T/21 cm VNMRS Direct Drive™ MR system (Varian Inc., Palo Alto, CA, USA) essentially as described previously^[@CVN101C20]^ on embryos at E15.5. Whole mount *in situ* immunostaining was performed on E9.5 embryos using anti-neurofilament antibody (clone 2H3, Developmental Studies Hybridoma Bank, University of Iowa, IA, USA).^[@CVN101C21]^ X-Gal and nuclear fast red (Sigma, St. Louis, MO, USA) staining were performed according to standard procedures.^[@CVN101C14],[@CVN101C16]^

2.5. Quantitative real time-polymerase chain reaction {#s2e}
-----------------------------------------------------

Embryo hearts (E13.5) were dissected out initially in DEPC treated phosphate-buffered saline (PBS), and then finely dissected in RNAlater (Ambion, Austin, TX, USA) to remove mediastinal tissue. Embryos at E8.5 were dissected free from the yolk sac in cold DEPC--PBS and flash-frozen in liquid nitrogen. RNA was isolated using a Nucleospin RNA purification kit (Clontech, Palo Alto, CA, USA), and an Archive cDNA kit (Ambion) used to synthesize complementary DNA. Quantitative RT-PCR (qRT-PCR) reactions were carried out using a Bio-Rad I-Cycler (Bio-Rad, CA, USA) and pre-optimized TaqMan® primer-probe sets from Applied Biosytems (*Mus musculus* assays Mm00516121_m1 (for NM_010828 *Cited2*), Mm00440826_m1 (for NM_001042502 *Pitx2c*), and eukaryotic 18S rRNA). Expression levels were normalized to 18S rRNA using the R~0~ method of analysis.^[@CVN101C22],[@CVN101C23]^ Multiplex reactions were performed with 18S rRNA and the TaqMan primer-probe set for the gene of interest. Data were normalized to the level obtained for 18S RNA in each case. All reactions were performed in triplicates and, as a quality control, only samples for which the threshold cycle (Ct) replicate values were within 1 Ct value of each other were used for subsequent analysis.^[@CVN101C24]^ Mean values for each reaction triplicate were analysed.

2.6. Statistical analyses {#s2f}
-------------------------

We used the chi-squared test for deviation from expected Mendelian ratios (<http://www.kursus.kvl.dk/shares/vetgen/_Popgen/genetik/applets/ki.htm>), and calculated probability of a type I error using the CHIDIST function in Microsoft Excel (Redmond, WA, USA). For analysis of the qRT-PCR data, we used a two-tailed, two-sample heteroscedastic *t*-test assuming unequal variance.

3.. Results {#s3}
===========

3.1. Deletion of *Cited2* in the epiblast {#s3a}
-----------------------------------------

To determine the role of *Cited2* in the epiblast it was deleted using *Sox2Cre* which induces recombination in all epiblast cells by E6.5.^[@CVN101C15]^. Genotyping of mice at weaning showed a complete absence of *Cited2^−/flox^*;*Sox2Cre* embryos, but genotyping at E15.5 showed that these embryos were present in the expected Mendelian ratio ([Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}). This indicated that *Cited2^−/flox^*;*Sox2Cre* embryos die either in late gestation or perinatally. Two of 10 *Cited2^−/flox^*;*Sox2Cre* embryos at E15.5 had visible exencephaly (not shown). Analysis of *Cited2^−/flox^*;*Sox2Cre* embryos at E15.5 using MRI showed that they frequently had a classical cardiac laterality defect, i.e. right-atrial isomerism, associated with right-pulmonary isomerism (six of 10 embryos) (*Figure [1](#CVN101F1){ref-type="fig"}*; see also see [Supplementary material online, *Table S2*](#sup1){ref-type="supplementary-material"}), indicating a defect in embryonic left--right patterning. VSDs were present in all embryos (see [Supplementary material online, *Table S2*](#sup1){ref-type="supplementary-material"}). The embryos invariably had adrenal agenesis (see [Supplementary material online, *Figure S2*](#sup1){ref-type="supplementary-material"}). No defects were seen in the 11 littermate control *Cited2^+/flox^*;*Sox2Cre* or in eight *Cited2^−/flox^* embryos.

![Deletion of *Cited2* in the epiblast: cardiac morphology. Magnetic resonance imaging of E15.5 embryos. (A--D) Transverse sections and three-dimensional (3D) reconstructions (dorsal views) of *Cited2^+/flox^;Sox2Cre* (control) and *Cited2^−/flox^;Sox2Cre* hearts. (*A*, *B*) Control normal heart showing a pectinated (P) right atrium (RA), with a systemic venous sinus (SVS), into which drains the right superior caval vein (RSCV), the left superior caval vein (LSCV) via the coronary sinus (CS) and the inferior caval vein (ICV). The left atrium (LA) is characterized by the primary atrial septum (PAS). Other structures seen are right and left ventricles (RV, LV), interventricular septum (IVS), and the mitral and tricuspid valves (MV, TV not labelled). (*C*, *D*) *Cited2^−/flox^;Sox2Cre* heart showing a large primum atrial septal defect (ASDP), resulting in a common atrium (A). This is pectinated on each side and has bilateral systemic venous sinuses (LSVS, RSVS), into which drains the bilateral superior and inferior caval veins. The coronary sinus is absent. These appearances indicate right atrial isomerism. A common atrioventricular valve (CAVV) over-rides a ventricular septal defect (VSD). Note also that the heart is malpositioned to the right. (E--J) Coronal sections and 3D reconstructions (ventral views) of *Cited2^+/flox^;Sox2Cre* (control) and *Cited2^−/flox^;Sox2Cre* hearts. (*E*, *F*) Control normal heart where the right ventricle is dextral to the left, and gives rise to the main pulmonary trunk (PT). The left ventricle gives rise to the aorta (Ao), which arches to the left of the trachea (Tr) over the left main bronchus. (*G*, *H*) *Cited2^−/flox^;Sox2Cre* heart with normal ventricular topology, cardiac dextroposition, and a right-sided aortic arch arising from the right ventricle. (*I*, *J*) *Cited2^−/flox^;Sox2Cre* heart with abnormal ventricular topology: the right ventricle is sinistral (and anterior) to the left ventricle. Scale bars = 500 µm; axes: D, dorsal; V, ventral; R, right; L, left; A, anterior; P, posterior.](cvn10101){#CVN101F1}

3.2. Deletion of *Cited2* in the neural crest {#s3b}
---------------------------------------------

To determine the requirement for *Cited2* in the neural crest it was deleted using *Wnt1Cre*, which drives expression of *Cre*-recombinase in all neural crest-derived tissues, including the cardiac neural crest, from E9.^[@CVN101C16],[@CVN101C25],[@CVN101C26]^ There was a significant reduction in the numbers of *Cited2^−/flox^;Wnt1Cre* mice in comparison with *Cited2^+/flox^;Wnt1Cre* mice at weaning \[21 of 61 vs. 40 of 61, respectively (*χ*^2^ = 5.9; *P* \< 0.015). There was no observed reduction when genotyping was performed between E9.5 and E18.5. Examination of embryos at E15.5--E18.5 (*n* = 16) using MRI revealed none with heart or great vessel defects, but one embryo had exencephaly (*Figure [2](#CVN101F2){ref-type="fig"}B*). Exencephaly was not observed in *Cited2^+/flox^;Wnt1Cre* embryos (*n* = 16). Examination of cranial ganglia by anti-neurofilament staining in *Cited2^−/flox^;Wnt1Cre* embryos showed that 11 of 14 sets had fusions of ganglia IX and X (*Figure [2](#CVN101F2){ref-type="fig"}E* and *F*) and hypomorphic ganglia V and VII/VIII. In contrast, two of 28 sets of ganglia from *Cited2^+/flox^;Wnt1Cre* embryos had fusions of ganglia IX and X (*χ*^2^ = 22.28; *P* \< 0.001). In both *Cited2^−/flox^;Wnt1Cre* and in *Cited2^+/flox^;Wnt1Cre* embryos, we observed extensive *lacZ* staining in the cranial mesenchyme, and in the first and second pharyngeal arches (*Figure [2](#CVN101F2){ref-type="fig"}G* and *H*). Staining was also observed in the cardiac neural crest (the third and fourth/sixth pharyngeal arches). The staining pattern corresponded to that described with *Wnt1Cre*-driven recombination in R26R mice that express *lacZ* conditional to *Cre*-mediated recombination.^[@CVN101C16]^

![Deletion of *Cited2* in the neural crest. Control (*Cited2^+/flox^;Wnt1Cre*, left panels) and mutant (*Cited2^−/flox^;Wnt1Cre*, right panels) embryos were analysed at different stages of development. (*A*, *B*) Control and mutant E17.5 embryos, respectively. The mutant embryo has exencephaly. (*C*, *D*) Magnetic resonance imaging (MRI) transverse sections of E17.5 control and mutant embryos. No cardiac or aortic arch abnormalities were identified in 14 mutant embryos examined by MRI. (*E*, *F*) Anti-neurofilament antibody staining of control and mutant E9.5 embryos showing cranial ganglia. The fifth (trigeminal ganglion) is smaller, and the ninth and tenth (glossopharyngeal and vagal) ganglia are fused in the mutant. (*G*, *H*) *LacZ* staining of control and mutant embryos. Extensive staining is observed in the cranial mesenchyme, and in the first and second pharyngeal arches. Staining is also observed in the cardiac neural crest (the third and fourth/sixth pharyngeal arches). No difference was observed in either case. The otic vesicle (O) is indicated. Axes and abbreviations are as shown in *Figure [1](#CVN101F1){ref-type="fig"}*.](cvn10102){#CVN101F2}

3.3. Deletion of *Cited2* in the mesoderm {#s3c}
-----------------------------------------

The role of *Cited2* in the cranial, cardiac, and extraembryonic mesoderm was examined by deletion using crosses with *Mesp1Cre* mice, which deletes in these tissues by E7.5.^[@CVN101C17],[@CVN101C27]^ As this *Cre* allele is a 'knockin' and disrupts the endogenous gene, we analysed genotypic ratios of offspring born by crossing these lines with *Cited2^+/−^* mice to determine if there was a genetic interaction. The number of *Cited2^+/−^;Mesp1Cre^+/KI^* mice at weaning was similar to *Cited2^+/+^;Mesp1Cre^+/KI^* mice indicating no significant genetic interaction ([Supplementary material online, *Table S3*](#sup1){ref-type="supplementary-material"}). Isolated septal defects (but no outflow or aortic arch defects) were seen in three of 18 *Cited2^−/flox^;Mesp1Cre* embryos and no defects were seen in the seven *Cited2^+/flox^;Mesp1Cre* or nine *Cited2^−/flox^* littermate control embryos studied ([Supplementary material online, *Figure S3*](#sup1){ref-type="supplementary-material"}). The deletion of *Cited2* using a *TCre* driver was then investigated. This would be expected to delete extensively in the lateral-plate, intermediate, and paraxial mesoderm and the hindgut endoderm, with earliest deletion being detected by E7.5^[@CVN101C18]^. Deletion of *Cited2* using *TCre* resulted in frequent adrenal agenesis (10 of 14 embryos), and infrequent cardiac septal and left--right patterning defect (three of 14 and one of 14, respectively, *Figure [3](#CVN101F3){ref-type="fig"}*). No defects were identified in the 11 *Cited2^+/flox^;TCre* littermate control embryos studied.

![Deletion of *Cited2* using *TCre*. Control (*Cited2^+/flox^;TCre*, left panels) and mutant (*Cited2^−/flox^;TCre*, right panels) embryos were analysed at E15.5 using magnetic resonance imaging. (*A*) Transverse section of a control embryo showing normal cardiac anatomy. (*B*) Corresponding transverse section from the single mutant embryo (of 14 analysed) that showed a laterality defect. Right atrial isomerism is indicated by bilateral systemic venous sinuses and a common atrium created by complete absence of the primary atrial septum. The heart is dextroposed, with abnormal ventricular topology \[dextral left ventricle (LV)\] and a ventricular septal defect. (*C*) Three-dimensional (3D) reconstruction of the control embryo heart showing normal topology of the ventricles. The aorta (Ao) arises from the LV, and pulmonary trunk (PT) from the right ventricle (RV). Both Ao and PT arch over the left main bronchus (LMB). (*D*) 3D reconstruction of the mutant embryo heart showing abnormal ventricular topology. Both Ao and PT arise from the RV and arch over the LMB. (*E*) Sagittal section through the control embryo showing normal pulmonary topology. The three lobes of the right lung are seen. The left lung (LL) has a single lobe. (*F*) Sagittal section through the mutant embryo showing right pulmonary isomerism. Both lungs have three lobes. A fused accessory (Ac) lobe is also seen. (*G*, *H*) Sagittal sections through the left kidney (LK) of control and mutant embryos, respectively. The adrenal gland (Ad) is seen in the control but not in the mutant embryo. Scale bars = 500 µm. Axes and abbreviations are as shown in *Figure [1](#CVN101F1){ref-type="fig"}*.](cvn10103){#CVN101F3}

3.4. Analysis of *Cited2* recombination {#s3d}
---------------------------------------

### 3.4.1. *LacZ* staining {#s3d1}

The above results indicate that *Cited2* deficiency induced by *Wnt1Cre*, *Mesp1Cre*, or *TCre* drivers cannot explain either the phenotypic heterogeneity or penetrance of cardiac malformation and left--right patterning defects observed in the epiblast-specific deletion of *Cited2*. To explore the mechanism and evaluate the efficiency of recombination we examined the expression of *lacZ* in these different *Cited2^+/flox^;Cre* embryos at E9.5 in comparison with *Cited2^+/flox^;Sox2Cre* (*Figure [4](#CVN101F4){ref-type="fig"}* and [Supplementary material online, *Table S4*](#sup1){ref-type="supplementary-material"}). Deletion of exon 2 by *Cre*-recombinase brings the *lacZ* cassette under control of the endogenous *Cited2* promoter, so analysis of *lacZ* expression allowed the confirmation of *Cited2^flox^* recombination in the embryonic lineages where both the *Cre* driver and *Cited2* are expressed. In the heart, we observed staining resembling the *Sox2Cre* pattern using *Mesp1Cre*, consistent with effective recombination in the cardiogenic mesoderm.^[@CVN101C17],[@CVN101C27]^ Reduced *lacZ* staining was observed in the outer curvature of the left ventricle suggesting that *Cited2* is not highly expressed here (*Figure [4](#CVN101F4){ref-type="fig"}*). With *TCre* we observed complete recombination in the common atrial chamber, but partial recombination in the atrioventricular canal, primitive ventricle, bulbus cordis, and outflow tract. The lateral plate mesoderm is thought to play a key role in establishing left--right patterning (reviewed in Hamada *et al*.^[@CVN101C10]^). We therefore examined the expression of *lacZ* in structures derived from the lateral plate mesoderm: these include the mesenchyme of the body wall (somatopleure) and of the viscera (splanchnopleure).^[@CVN101C28]^ In *Cited2^+/flox^;Sox2Cre* embryos, strong *lacZ* expression was observed in the splanchnopleure, and weaker expression in the somatopleure. With *TCre* and *Mesp1Cre*, *lacZ* expression was detected chiefly in the posterior splanchnopleure surrounding the midgut. No *lacZ* staining was detected in the somatopleure.

![*LacZ* expression in *Cited2^+/flox^;Cre* embryos. The left panels show pictures of embryos (E9.5) with the indicated genotypes after staining for *lacZ*. Subsequent panels show transverse embryo sections counterstained with nuclear fast red. ACV, anterior cardinal vein; AVC, atrioventricular canal; BA, branchial arch; BC, bulbus cordis; CAC, common atrial chamber; CCV, common cardinal vein; DA, dorsal aorta; FG, foregut; HD, hepatic diverticulum; HG, hindgut; HGD, hindgut diverticulum; HM, head mesenchyme; LB, lung bud; LM, lateral mesenchyme from splanchnopleure; MG, midgut; NC, nephric cord (intermediate mesenchyme); NT, neural tube; OFT, outflow tract; PC, peritoneal cavity; PPC, pleuroperitoneal canal; PV, primitive ventricle; ST, septum transversum; S, somite. Scale bars = 500 µm. Axes are as shown in *Figure [1](#CVN101F1){ref-type="fig"}*.](cvn10104){#CVN101F4}

We also examined *lacZ* expression at earlier developmental stages ([Supplementary material online, *Figure S4*](#sup1){ref-type="supplementary-material"}). At earlier stages, in *Cited2^+/flox^;Sox2Cre* embryos at E7.5, *lacZ* expression was present in all epiblast-derived tissues, including the extraembryonic mesoderm. In *Cited2^+/flox^;TCre* embryos, we observed *lacZ* staining in the extraembryonic mesoderm, amnion, and blood islands, and also to some extent in the nascent embryonic mesoderm. This became more extensive in the primitive streak and migrating embryonic mesoderm at slightly later stages. Examination of head-fold stage *Cited2^+/flox^;Mesp1Cre* embryos showed extensive recombination in the cardiac crescent ([Supplementary material online, *Figure S4*](#sup1){ref-type="supplementary-material"}).

### 3.4.2. Quantitative real-time polymerase chain reaction {#s3d2}

To verify efficient deletion of *Cited2* in the *Sox2Cre* and *Mesp1Cre* conditional knockouts at the mRNA level, and to determine the effect on the *Cited2* target gene *Pitx2c*, qRT-PCR was performed. *Cited2* expression was reduced 7474-fold (*P* = 0.00017) in *Cited2^−/flox^;Sox2Cre* hearts compared with littermate controls (*Figure [5](#CVN101F5){ref-type="fig"}A*). There was also a 3.1-fold reduction in *Pitx2c* expression (*P* = 0.013; *Figure [5](#CVN101F5){ref-type="fig"}B*). *Cited2* expression was reduced 130-fold in *Cited2^−/flox^;Mesp1Cre* hearts compared with littermate controls (*Figure [5](#CVN101F5){ref-type="fig"}C*). However, no reduction in *Pitx2c* expression was seen in these hearts (*Figure [5](#CVN101F5){ref-type="fig"}D*).

![*Cited2* and *Pitx2c* mRNA levels in *Cited2* conditionally deleted hearts at E13.5. Sample mean and SEM are indicated. (*A*) *Cited2* mRNA levels were reduced 7474-fold in *Cited2^−/flox^;Sox2Cre* hearts compared with controls. (*B*) A significant 3.1-fold decrease in *Pitx2c* mRNA levels was found in *Cited2^−/flox^;Sox2Cre* hearts compared with controls. (*C*) In *Cited2^−/flox^;Mesp1Cre* hearts, *Cited2* levels were reduced 130-fold compared with controls. (*D*) No significant difference in *Pitx2c* expression was found between *Cited2^−/flox^;Mesp1Cre* hearts and controls.](cvn10105){#CVN101F5}

3.5. *Cited2* haploinsufficiency in the mouse {#s3e}
---------------------------------------------

The mutations found in human congenital heart disease patients^[@CVN101C12]^ suggested that *Cited2* haploinsufficiency may occur. We tested for this in the mouse by examining the genotypic ratios of *Cited2^+/−^* intercrosses where we obtained 500 wild-type and 782 *Cited2^+/−^* pups (expected 855). The 8.5% reduction in *Cited2^+/−^* pups was statistically significant (*χ*^2^ = 18.5; *P* \< 0.0001). A similar reduction was not observed however when the genotypic ratios of E13.5 or E15.5 embryos were examined ([Supplementary material online, *Table S5*](#sup1){ref-type="supplementary-material"}).

To determine a mechanism for reduced survival, we examined *Cited2^+/−^* embryos at E15.5 by MRI (*Figure [6](#CVN101F6){ref-type="fig"}*). This was followed by histological sectioning of embryos that had either oedema or a cardiac abnormality visible on MRI. We found that three of 45 *Cited2^+/−^* embryos had a clearly identifiable VSD, and one presented with DORV with hypoplastic pulmonary trunk (*Figure [6](#CVN101F6){ref-type="fig"}*). These defects were not seen in the wild-type littermate controls. Thus, heterozygosity for a *Cited2* null allele is associated, at low penetrance, with cardiac malformation in the mouse, implying haploinsufficiency.

![Oedema and cardiac malformations in *Cited2^+/−^* embryos. Magnetic resonance imaging of wild-type and littermate *Cited2^+/−^* embryos at E15.5. Sagittal sections of wild-type (*A*) and *Cited2^+/−^* (*B*) embryos. Severe oedema (asterisks) is seen in the *Cited2^+/−^* embryo. (*C*) Transverse section of wild-type and *Cited2^+/−^* embryos. The *Cited2^+/−^* embryo has a ventricular septal defect (VSD) (*D*). (*E, F*) Three-dimensional reconstruction of the heart in the wild-type and *Cited2^+/−^* embryos shown in the previous panel. The aorta (Ao) and pulmonary artery (PA) arise from the left ventricle and right ventricle (RV), respectively, in the wild-type embryo, but in the *Cited2^+/−^* embryo they arise from the RV creating a double-outlet right ventricle (DORV). VSD is indicated. Scale bars, 500 µm. Axes are as shown in *Figure [1](#CVN101F1){ref-type="fig"}*.](cvn10106){#CVN101F6}

3.6. Quantitative real-time-polymerase chain reaction analysis of *Pitx2c* and *Cited2* expression {#s3f}
--------------------------------------------------------------------------------------------------

To determine if haploinsufficiency in *Cited2*-deficient hearts is linked to abnormality in *Pitx2c* expression, we examined gene expression using qRT-PCR. Embryos and hearts on a C57BL/6J background, generated by backcrossing for 14 generations, were used to minimize the effects of genetic background. Hearts at E13.5 were used as this is a key time-point in cardiac septation, and embryos at E8.5 were selected as *Pitx2c* is expressed asymmetrically in the left lateral plate mesoderm at this stage. In E13.5 hearts, *Cited2* was reduced 2.13-fold in *Cited2^+/−^* compared with wild-type (*P* = 2.62 × 10^−6^) (*Figure [7](#CVN101F7){ref-type="fig"}A*). We found that the *Cited2* mRNA in *Cited2^−/−^* hearts was either undetectable or, if detectable, had values ranging between 1.45 × 10^−12^ and 3.47 × 10^−11^ relative to 18S (*Figure [7](#CVN101F7){ref-type="fig"}C*), likely to represent the limits of the assay. The *Cited2* target gene *Pitx2c* was reduced 1.5-fold in *Cited2^+/−^* (*P* = 0.038) hearts and 4.7-fold (*P* = 0.00031) in *Cited2^−/−^* hearts compared with wild-type controls (*Figure [7](#CVN101F7){ref-type="fig"}B* and *D*). *Cited2* and *Pitx2c* mRNA were strongly correlated in wild-type and *Cited2^+/−^* hearts (Pearson rank correlation = 0.68, *P* = 0.0009; *Figure [7](#CVN101F7){ref-type="fig"}F*). In the E8.5 embryos, we found a two-fold reduction in *Pitx2c* levels in *Cited2^+/−^* compared with wild-type (*P* = 0.009; *Figure [7](#CVN101F7){ref-type="fig"}E*).

![*Cited2* and *Pitx2c* mRNA levels in E13.5 embryo hearts and E8.5 embryos. Sample mean and SEM are indicated. (*A*) A 2.1-fold reduction in *Cited2* mRNA levels was seen in *Cited2*^+/−^ hearts compared with wild-type. (*B*) *Pitx2c* levels were reduced 1.5-fold in *Cited2^+/−^* hearts compared with wild-type. (*C*) A 92 000-fold reduction in *Cited2* mRNA is seen in the *Cited2*^−/−^ hearts compared with wild-type. (*D*) *Pitx2c* mRNA levels were reduced 4.7-fold in the *Cited2*^−/−^ hearts compared with wild-type. (*E*) *Pitx2c* levels in wild-type and *Cited2^+/−^* E8.5 embryos. A two-fold reduction in *Pitx2c* mRNA is seen in the *Cited2*^+/−^ embryos. (*F*) Pearson correlation between *Cited2* and *Pitx2c* E13.5 heart mRNA levels with line-of-best-fit and 95% confidence intervals (dotted lines) shown. Filled circles represent data from *Cited2^+/−^* hearts and diamonds those from wild-type. *Cited2* and *Pitx2c* mRNA levels were strongly correlated in wild-type and *Cited2^+/−^* hearts.](cvn10107){#CVN101F7}

4.. Discussion {#s4}
==============

In these experiments, we used a conditional knockout approach to understand how *Cited2* deficiency results in cardiac phenotypic heterogeneity. To define the role of *Cited2* in the epiblast, we deleted it with *Sox2Cre*.^[@CVN101C15]^ This resulted in 100% penetrance of cardiovascular malformations and adrenal agenesis. The most common cardiac malformation was a VSD, which was present in all embryos, and was associated with DORV in some embryos. In addition we observed left--right patterning, atrial septal, outflow tract, and aortic arch defects. These observations are consistent with, and fully recapitulate, those previously reported with the global deletion of *Cited2*.^[@CVN101C6],[@CVN101C29]^ They indicate that *Cited2* is essential in the epiblast or its derivatives for normal embryonic left--right patterning, and for cardiac and adrenal development. The complete penetrance of the defects, and the widespread expression of *lacZ* in embryos containing a *Cited2^flox^* allele and the *Cre* transgene also indicate that efficient recombination occurs in response to *Cre* expression. This was further validated by the large reduction seen in *Cited2* mRNA levels in the hearts of *Cited2^−/flox^;Sox2Cre* embryos. We observed reduced *lacZ* staining in the outer curvature of the left ventricle following conditional deletion of *Cited2* with *Sox2Cre* (as well as with *Mesp1Cre* and *TCre*). This is consistent with the published data,^[@CVN101C8]^ and indicates that *Cited2* is expressed at a lower level in this region of the heart.

To define the role of *Cited2* in the neural crest, we deleted it with *Wnt1Cre*.^[@CVN101C16],[@CVN101C30]^ This resulted in cranial ganglia fusions and exencephaly, but did not affect cardiac septal, outflow tract, aortic arch or adrenal development, or left--right patterning. These results indicate that although *Cited2* does have a cell autonomous role in the neural crest, as evidenced by fusion of the cranial ganglia, it is not required here for outflow tract septation or aortic arch patterning.

To determine the requirement of *Cited2* in the cranial, cardiac, and extraembryonic mesoderm it was deleted with *Mesp1Cre*, which results in extensive recombination in these tissues by E7.5.^[@CVN101C17],[@CVN101C27]^ Subsequently, by E9.5, recombination is observed extensively in myocardium and endocardium including the mesenchyme of the cono-truncal and atrioventricular cushions, in the epicardium, and in the pharyngeal arch mesoderm and vascular endothelium.^[@CVN101C17],[@CVN101C27],[@CVN101C31]^ Deletion of *Cited2* using *Mesp1Cre* resulted in low penetrance of septal defect, and no outflow tract, aortic arch, or laterality defects. These results indicate that *Cited2* function in the mesoderm does not explain the phenotypically heterogeneic cardiac malformations observed in the epiblast-specific deletion. Efficient recombination at the *Cited2* locus in response to *Cre* expression as demonstrated by *lacZ* staining and qRT-PCR indicated that lack of a phenotypically heterogeneic phenotype is unlikely to be owing to inefficient recombination.

As *Cited2* is expressed in the lateral-plate mesoderm,^[@CVN101C8]^ and as its deficiency also leads to loss of *Nodal*-activated transcripts such as a *Nodal*, *Lefty2*, and *Pitx2c* in the left-lateral plate mesoderm,^[@CVN101C7],[@CVN101C8]^ we investigated its role here by deletion using *TCre*.^[@CVN101C18]^ This resulted in infrequent septal and laterality defect. Deletion of *Cited2* induced by *TCre* was predominantly in the posterior rather than the anterior extent of the lateral plate mesoderm, making this one possible mechanism for the infrequency of left--right patterning defect observed with a *TCre*-induced deletion. The *lacZ* staining pattern seen in *Cited2^+/flox^;TCre* embryos was comparable with that seen with *TCre × R26R lacZ* embryos.^[@CVN101C18]^ Moreover, in the heart the staining pattern was highly reminiscent of that observed for *Isl1*^[@CVN101C32]^ suggesting that *TCre* may also drive recombination in second heart field-derived regions of the heart. These results indicate that the penetrant and phenotypically heterogeneic cardiac malformations in *Cited2* deficiency arise from a primary requirement in epiblast derivatives for left--right patterning with a secondary cell-autonomous role in the mesoderm for septation. A limitation of our studies, however, is that the role of *Cited2* in the endoderm---which has a major role in cardiac induction^[@CVN101C33]^---could not be established. We are currently limited here by the lack of a suitable *Cre* driver that expresses in the endoderm at the appropriate time-point.

Our data also show that *Cited2* haploinsufficiency occurs in the mouse and is associated with cardiac malformation. Although 8.5% of *Cited2* heterozygous pups are lost by weaning, consistent with the numbers of cardiac malformations observed, no deviation from expected numbers was seen during development. The mechanistic link between cardiac malformations and *Cited2* haploinsufficiency is unclear, and to address this, we quantitatively examined the expression of *Cited2* and its target gene *Pitx2c* in embryonic hearts and E8.5 embryos. Using qRT-PCR we showed that *Cited2* expression is significantly reduced in *Cited2* heterozygous embryonic hearts. We also showed that this was accompanied by a significant reduction in *Pitx2c* expression, and that the two were strongly correlated. We also observed a significant reduction in *Pitx2c* levels in E8.5 *Cited2^+/−^* embryos. As the dose of *Pitx2c* is crucial for normal left--right patterning and cardiac development,^[@CVN101C34],[@CVN101C35]^ we suggest that *Pitx2c* deficiency observed in *Cited2* heterozygous hearts and embryos could explain, at least in part, the observed cardiac malformations.

In conclusion, these results indicate that phenotypically heterogeneic and penetrant cardiac malformations in *Cited2* deficiency arise from a primary requirement in epiblast derivatives for left--right patterning with a secondary cell-autonomous role in the mesoderm for septation. Cardiac malformation associated with *Cited2* haploinsufficiency may occur by reducing the expression of key *Cited2* targets, such as *Pitx2c* from E8.5. Importantly, cardiovascular phenotypic heterogeneity is observed, for instance, with mutation in *NKX2-5*, ^[@CVN101C36]^*CFC1*^[@CVN101C39],[@CVN101C40]^ or *ZIC3*.^[@CVN101C41]^ Consistent with our proposed model, these genes, like *Cited2*, are also known to control or modulate left--right patterning pathways.^[@CVN101C42],[@CVN101C44]^ Our results support the emerging idea^[@CVN101C7],[@CVN101C11]^ that genes controlling early left--right patterning are candidates for diverse forms of human congenital heart disease, even in the absence of a classical laterality defect such as isomerism.
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